Retrophin Priced, Nasdaq: RTRX
Developing treatments for postpartum milk let-down, Schizophrenia and Autism.
Industry: Health Care
First Day Return: +35.2%
Industry: Health Care
RTRX
Developing treatments for postpartum milk let-down, Schizophrenia and Autism.
| IPO Data | |
|---|---|
| IPO File Date | 12/18/2013 |
| Offer Price | $8.50 |
| Price Range $8.30 - $8.30 | |
| Offer Shares (mm) | 4.7 |
| Deal Size ($mm) | $40 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 01/09/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $40 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | New York, NY, United States |
| Founded | 2008 |
| Employees at IPO | 22 |
| Website www.retrophin.com | |
IPO News for Retrophin
Retrophin (RTRX) Performance
